Medtronic Launches New Pediatric Monitor That Alerts Clinicians To Potential Airway Obstructions During Ventilation

Worldwide, 415,000 newborns and infants require invasive mechanical ventilation per year and are intubated for longer than 24 hours. Despite recommendations and reduction efforts, 75,000, or about one in five, of these neonates and infants will experience at least one unplanned extubation (UE). In the NICU, UEs are a major safety concern for neonates and neonates and are the most common adverse reaction during mechanical ventilation.1 These events can lead to longer hospital stays and hospital costs.2 Using the SonarMed Airway Monitoring System can reduce the frequency of these events, which in turn help improve outcomes and reduce healthcare costs.

“The SonarMed airway monitoring device has revolutionized the way we care for our smallest patients. There is no other device in the world that can continuously tell you in real time where the endotracheal tube is in the airway and whether the tube is blocked or even partially obstructed, ”said Jamie W. Powers, MD, MBA, neonatologist at Huntington Hospital in Pasadena, California. improving the effective suction of the airways. It also gives the care team and parents the added assurance that the breathing hose is in place. during patient repositioning and during kangaroo care. In our facility it has become the new standard of care for all intubated babies. “

The SonarMed Airway Monitoring System is the first and only FDA-approved airway monitoring system that provides timely alerts and specific measurements that enable a coordinated response in addressing potentially critical events such as ETT movement and migration.

“Physicians face unique challenges every day in the neonatal intensive care unit (NICU) and pediatric intensive care unit (PICU), ranging from managing oxygenation within extremely tight ranges to informing and comforting family members. patient group is continuously monitored with a real-time and accurate device that can help improve a physician’s ability to manage the airways and improve outcomes for our smallest, most vulnerable intensive care patients, ”said Ariel MacTavish, president of the department Respiratory Interventions, which is part of Medtronic’s Medical Surgical Portfolio. “Our goal with the introduction of SonarMed technology is to help solve a clinical need to reduce the number of unplanned extubations to help these vulnerable patients start their lives in the healthiest way.”

SonarMed, acquired by Medtronic in December 2020, specializes in developing solutions that increase patient safety and significantly reduce healthcare costs.

“With Medtronic’s extensive market presence, clinical leadership and market development expertise, coupled with SonarMed’s innovative technology, we believe that together we can potentially help save the lives of thousands of babies,” said Tom Bumgardner , Medtronic Strategic Planning Program Director. Respiratory interventions and former CEO of SonarMed.

For more information about the SonarMed Airway Monitoring System, visit:

About SonarMed ™ Airway Monitoring System
The SonarMed Airway Monitoring System includes a bedside monitor and a disposable sensor. The SonarMed sensor fits any brand of standard endotracheal tube (ETT) in sizes ranging from neonatal to pediatric populations (2.5mm-6.0mm ID) and attaches noninvasively to the proximal end of the ETT by the 15 -mm connector in the breathing circuit. The SonarMed monitor has an easy-to-read color screen that can display any change in ETT status.

About Medtronic
Medtronic plc (, headquartered in Dublin, Ireland, is one of the world’s largest medical technology, services and solutions companies – relieving pain, restoring health and extending the lives of millions people all over the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on partnering with stakeholders around the world to further bring healthcare together.

All forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from expected results.

The SonarMed Airway Monitoring System is not to be used as the sole basis for diagnosis or therapy and is intended only as an aid in patient assessment.

1 The adverse consequences of unplanned extubation in a cohort of critically ill newborns. 2019. KK Kambestad, A Huack, S Nair, R Chapman, S Chin, L Langga, E Mounger, E Guerrero, NP Iyer. 10.4187 / respcare.06721. Respiratory care.
2 Roddy DJ, Spaeder MC, Pastor W, Stockwell DC, Klugman D. Unplanned extubations in children: impact on hospital costs and length of stay. Pediatr Crit Care Med. 2015; 16 (6): 572-575. doi: 10.1097 / PCC.


Kira Jastive

Ryan Weispfenning

Public Relations

Investor Relations

+ 1-508-452-4238

+ 1-763-505-4626

SOURCE Medtronic plc

Related Links

Comments are closed.